4 European Projects Found
Searched on 125080 European Projects
FINISHED
Advanced Immunization Technologies (ADITEC)
Start date: Oct 1, 2011, End date: Sep 30, 2017,
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Read Project
53
Partners Participants
FINISHED
Vaccination against Shigella and ETEC: novel antigens, novel approaches (STOPENTERICS)
Start date: Nov 1, 2010, End date: Apr 30, 2017,
To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysa ...
Read Project
20
Partners Participants
FINISHED
Vaccine Design and Immune Responses (VADER)
Start date: Oct 1, 2012, End date: Sep 30, 2016,
The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they elicit. Close interaction between both sectors expedites vaccine development and, in the context of global health, this can translate to the saving of thousands of lives. Th ...
Read Project
2
Partners Participants
FINISHED
Genome-driven vaccine development for bacterial infections (GENDRIVAX)
Start date: Jan 1, 2011, End date: Dec 31, 2014,
The aim of the GENDRIVAX (GENome-DRIVen Vaccine) scientific programme is to develop novel prophylactic vaccines against invasive bacterial diseases caused by Salmonella and Neisseria. GENDRIVAX intends to combine the results of recent industrial research (novel platform technologies for producing highly affordable outer membrane antigen based vaccines for Gram-negative bacteria) with the detailed ...
Read Project
